Idenix Pharmaceuticals Earnings Per Share: -0.12
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
IDIX Earnings Per Share Rankings
| Overall | 16th percentile | 3790 of 4548 |
| Sector | 31st percentile | 357 of 525 in Healthcare |
| Industry | 44th percentile | 90 of 163 in Biotechnology |
IDIX Earnings Per Share Range, Past 5 Years
| Minimum | -1.68 | Jun 2003 |
| Maximum | 0.53 | Jun 2004 |
| Average |
About Earnings per Share
Earnings per share (EPS) the amount of income that "belongs" to each share of common stock. An important tool for investors, EPS is often used in determining the value of a stock.
The average number of shares outstanding (the denominator of the EPS formula) is usually calculated by averaging the number of shares at the beginning of the earning period and the number of shares at the end of the period. For example, if a company earned $1 million in 2009 and had 900,000 shares at the beginning of 2009 and 1.1 million shares at the end of 2009, the 2009 EPS would be $1 million/[(.9 million shares + 1.1 million shares)/2] = $1/share.
EPS is generally reported in annualized form from the most recent fiscal year. From time to time, you will see the abbreviation (ttm) associated with earnings per share. That means that the earnings number is a sum of the previous four quarters, which is not necessarily the same as the previous fiscal year.
Learn More
You may also be interested in these IDIX related companies
IDIX News
@js_thorne $IDIX Alot going on behind the scenes so it CAN only be good going forward is my guess.
about 8 hours ago by GArgondizza
about 8 hours ago by GArgondizza
$IDIX big guys flushing stock and accumulating large positions?? That's my interperprtation of SEC filings
about 11 hours ago by js_thorne
about 11 hours ago by js_thorne
@StockRaker You were smart $IDIX. The table's been set on this one.
about 13 hours ago by taketheplunge
about 13 hours ago by taketheplunge
@GArgondizza @StockRaker you too my man, $idix im in it to win it just like i did with $inhx :)
about 23 hours ago by BILLYTHE3RD
about 23 hours ago by BILLYTHE3RD
@pjeffry000 @Eowen57 $idix Sorry about that volume, when i plugged in the stock i assumed the bid n ask and volume was all connected.
about 23 hours ago by GArgondizza
about 23 hours ago by GArgondizza
@fukuyama09 $SODA $ONTY $IDIX Everybody Hurts. great picks, stay tuned, be prudent....Holding. Take a look at $CLDX as well. Great pipe
about a day ago by NHStocktrdr
about a day ago by NHStocktrdr
RT @GArgondizza $IDIX 2.2 million shares AH more then all day? Hmmm, 86k http://stks.co/2MAv
about a day ago by Eowen57
about a day ago by Eowen57
RT @GArgondizza $IDIX 2.2 million shares AH more then all day? Hmmm >> negative - seeing only 86K AH one of us is wrong
about a day ago by StockRaker
about a day ago by StockRaker
$IDIX big fish come in at the right time, not after, not before. in my hopeful opinion...
about a day ago by littleguy
about a day ago by littleguy
@GArgondizza $IDIX It means some people spending millions of dollars buying stock in a company they must see ass greatly underappreciatied.
about a day ago by BILLYTHE3RD
about a day ago by BILLYTHE3RD
Barclays on U.S. Pharma: A New Era for Hep C Therapy - Starts Coverage on GILD & IDIX
Feb 10, 2:30PM Street Insider
Feb 10, 2:30PM Street Insider
Notable Analyst Rating Changes 02/10: (COP) (JDSU) (ATVI) Upgraded; (ORLY) (XCO) (AKS) Downgraded
Feb 10, 11:17AM Street Insider
Feb 10, 11:17AM Street Insider
A Forward Look, the Year Ahead - Featured Research on Inhibitex, Inc. and Idenix Pharmaceuticals, Inc.
Feb 07, 9:00AM Marketwire
Feb 07, 9:00AM Marketwire
Idenix (IDIX) announces removal of partial clinical hold on HCV nucleotide inhibitor, IDX184
Feb 03, 8:04AM Street Insider
Feb 03, 8:04AM Street Insider
Idenix Announces Removal of the Partial Clinical Hold on HCV Nucleotide Inhibitor, IDX184
Feb 03, 8:04AM Benzinga
Feb 03, 8:04AM Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| IDIX | 10.92 | -0.21 | -1.89% | 1.05B |
| DE | 87.55 | -0.38 | -0.43% | 36.24B |
| SMSC | 26.97 | -0.22 | -0.81% | 615.19M |
| FSYS | 24.16 | -0.08 | -0.33% | 482.72M |
| TM | 78.39 | -2.49 | -3.08% | 122.90B |
| LTS | 2.06 | 0.06 | 3.00% | 377.25M |
| NRG | 17.32 | 0.24 | 1.41% | 4.18B |
| JMP | 7.40 | -0.10 | -1.33% | 165.69M |
| GSK | 44.75 | -0.31 | -0.69% | 114.07B |
| DIT | 65.30 | 0.03 | 0.04% | 40.48M |
